BioSpace News Archive

Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) in presently in the midst of a Phase 3 study of givosiran, reporting that the drug has been successful in a clinical trial. The company hopes to use their trial data in getting givosiran approved by the U.S. Food and Drug Administration (FDA).

Quanticate, has announced that it has partnered with CluePoints™ to utilize their software to drive the statistical analysis to perform data integrity checks on all types of monitoring and investigator site data as part of its new Data Quality Oversight service that enables centralized statistical monitoring, in response to the amendments to the ICH Good Clinical Practice (GCP) E6(R2) guidelines.

Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment

An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. The two-drug combination is capable of suppressing HIV for months at a time, according to a study published by The Rockefeller University.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Aldeyra Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share.

Athletico Physical Therapy has opened a new location in Bensenville on Monday, September 24th at 460 W. Irving Park Rd., Suite G, Bensenville, IL 60106. Athletico is looking forward to continuing its quality of care throughout the Chicagoland area.

This week marks the official start of “flu season” for 2018-2019. The FDA, along with its partners across the Department of Health and Human Services, has been working throughout the year to prepare the development of a safe, effective flu vaccine for the season.

The board of directors of Pfizer Inc.. today declared a 34-cent fourth-quarter 2018 dividend on the company’s common stock, payable December 3, 2018, to shareholders of record at the close of business on November 9, 2018.